Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease

BACKGROUND: Oncostatin M (OSM) has been implicated in the pathogenesis of inflammatory bowel disease (IBD) and as a marker for nonresponsiveness to anti-tumor necrosis factor (TNF) therapy. We further unraveled the potential of OSM and related receptors as markers of diagnosis, prognosis, and therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstockt, Sare, Verstockt, Bram, Machiels, Kathleen, Vancamelbeke, Maaike, Ferrante, Marc, Cleynen, Isabelle, De Hertogh, Gert, Vermeire, Séverine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Leading Off
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522791/
https://www.ncbi.nlm.nih.gov/pubmed/33624092
http://dx.doi.org/10.1093/ibd/izab032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522791/
https://www.ncbi.nlm.nih.gov/pubmed/33624092
http://dx.doi.org/10.1093/ibd/izab032

Ejemplares similares